Indusatumab
Based on 1 Customer Validation
Indusatumab (5F9 Monoclonal antibody) is a monoclonal antibody against human GUCY2C (Guanylate cyclase 2C). Indusatumab fails to bind to granulocytes or erythrocytes. Indusatumab can be used to synthesize ADCs, such as Indusatumab vedotin (HY-P99662). Indusatumab can be used in cancer research.
For research use only. We do not sell to patients.
- Purity: ≥99.0%
- CAS No.: 1497400-26-6
- Molecular Weight:145.206 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Human IgG1 kappa
Human
GUCY2C
Indusatumab fails to bind to granulocytes or erythrocytes[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Loaded Indusatumab on AHC2 biosensor, can bind GUCY2C/Guanylyl cyclase C Protein, Human (Biotinylated, HEK293, His-Avi, HY-P77944) with an affinity constant of 2.157E-08 M as determined in BLI assay. -
Immobilized Hu-GUCY2C-his can bind Indusatumab. The EC50 for this effect is 4.769 ng/mL.
Chemical Information
-
CAS No. 1497400-26-6
-
Appearance Liquid
-
Molecular Weight 145.206 kDa
-
Color Colorless to light yellow
-
SMILES
[Indusatumab]
-
Synonyms
5F9 Monoclonal antibody; TAK-164 Antibody
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (256 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. e Goeij BE, et al. New developments for antibody-drug conjugate-based therapeutic approaches. Curr Opin Immunol. 2016 Jun;40:14-23. [Content Brief]
[2]. Khazaeli MB, et al. Development and characterization of a monoclonal antibody to human embryonal carcinoma. J Urol. 1987 Jun;137(6):1295-9. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)